A phase I study comparing the safety, pharmacokinetics, and pharmacodynamics of infliximab administered by the subcutaneous, intravenous followed by subcutaneous, or intramuscular routes of administration in rheumatoid arthritis patients. Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Westhovens, R
  • Hollssiau, FA
  • Joly, J
  • Daniel, Edwin Embrey
  • Bouman-Thio, E
  • Sisco, D
  • van Hartingsveldt, B
  • Mascelli, MA
  • Zhu, YW
  • Graham, MA
  • Durez, P

publication date

  • September 1, 2004